{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:27:12Z","timestamp":1791923232270,"version":"4.3.4"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T00:00:00Z","timestamp":1737072000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T00:00:00Z","timestamp":1737072000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The Scientific Research Project of Guangdong Provincial Bureau of Traditional Chinese Medicine","award":["2022ZYYJ01"],"award-info":[{"award-number":["2022ZYYJ01"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Interstitial lung disease (ILD) has shown limited treatment advancements, with minimal exploration of circulating protein biomarkers causally linked to ILD and its subtypes beyond idiopathic pulmonary fibrosis (IPF). In this study, we aimed to identify potential drug targets and circulating protein biomarkers for ILD and its subtypes. We utilized the most recent large-scale plasma protein quantitative trait loci (pQTL) data detected from the antibody-based method and ILD and its subtypes\u2019 GWAS data from the updated FinnGen database for Mendelian randomization analysis. To enhance the reliability of causal associations, we conducted external validation and sensitivity analyses, including Bayesian colocalization and bidirectional Mendelian randomization analysis. Our study identified eight plasma proteins genetically associated with ILD or its subtypes. Among these, three proteins\u2014CDH15 (Cadherin-15), LTBR (Lymphotoxin-beta receptor), and ADAM15 (A disintegrin and metalloproteinase 15)\u2014emerged as priority biomarkers and potential therapeutic targets, demonstrating more reliable associations by passing a series of sensitivity analyses compared to the others. Based on these findings, we propose for the first time that CDH15, ADAM15, and LTBR hold promise as novel potential circulating protein biomarkers and therapeutic targets for the diagnosis and treatment of ILD, IPF, and sarcoidosis, respectively, especially ADAM15, and these findings have the potential to provide new perspectives for advancing the research on the heterogeneity of ILD.<\/jats:p>","DOI":"10.1038\/s41598-025-85338-y","type":"journal-article","created":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T13:11:22Z","timestamp":1737119482000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Proteome-wide mendelian randomization identifies causal plasma proteins in interstitial lung disease"],"prefix":"10.1038","volume":"15","author":[{"given":"Kunrong","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjie","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanting","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huili","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,17]]},"reference":[{"key":"85338_CR1","doi-asserted-by":"publisher","first-page":"1296890","DOI":"10.3389\/fmed.2024.1296890","volume":"11","author":"MA Althobiani","year":"2024","unstructured":"Althobiani, M. A. et al. Interstitial lung disease: A review of classification, etiology, epidemiology, clinical diagnosis, pharmacological and non-pharmacological treatment. Front Med. (Lausanne) 11, 1296890 (2024).","journal-title":"Front. Med. (Lausanne)"},{"key":"85338_CR2","doi-asserted-by":"crossref","unstructured":"Ruaro, B. et al. Editorial: Pulmonary fibrosis: One manifestation, various diseases. Front. Pharmacol. 13, (2022).","DOI":"10.3389\/fphar.2022.1027332"},{"key":"85338_CR3","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s12931-024-02731-3","volume":"25","author":"K Buschulte","year":"2024","unstructured":"Buschulte, K. et al. Disease trajectories in interstitial lung diseases\u2014Data from the EXCITING-ILD registry. Respir Res. 25, 113 (2024).","journal-title":"Respir. Res."},{"key":"85338_CR4","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.3390\/biomedicines11123109","volume":"11","author":"M Giriyappagoudar","year":"2023","unstructured":"Giriyappagoudar, M., Vastrad, B., Horakeri, R. & Vastrad, C. Study on potential differentially expressed genes in idiopathic pulmonary fibrosis by bioinformatics and next-generation sequencing data analysis. Biomedicines. 11, 3109 (2023).","journal-title":"Biomedicines"},{"key":"85338_CR5","doi-asserted-by":"publisher","first-page":"6729","DOI":"10.2147\/JIR.S458428","volume":"17","author":"M Liu","year":"2024","unstructured":"Liu, M. et al. A pilot HRCT follow-up study to test the feasibility of predictive efficacy of serum periostin in idiopathic pulmonary fibrosis. J Inflamm Res. 17, 6729\u20136742 (2024).","journal-title":"J. Inflamm. Res."},{"key":"85338_CR6","doi-asserted-by":"publisher","first-page":"608","DOI":"10.3390\/medicina56110608","volume":"56","author":"F Salton","year":"2020","unstructured":"Salton, F., Ruaro, B., Confalonieri, P. & Confalonieri, M. Epithelial-mesenchymal transition: A major pathogenic driver in idiopathic pulmonary fibrosis? Medicina (Kaunas) 56, 608 (2020).","journal-title":"Medicina (Kaunas)"},{"key":"85338_CR7","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.3390\/ph15081033","volume":"15","author":"B Ruaro","year":"2022","unstructured":"Ruaro, B. et al. Gastroesophageal reflux disease in idiopathic pulmonary fibrosis: Viewer or actor? To treat or not to treat? Pharmaceuticals (Basel) 15, 1033 (2022).","journal-title":"Pharmaceuticals (Basel)"},{"key":"85338_CR8","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1007\/s00408-020-00383-w","volume":"198","author":"N Jeganathan","year":"2020","unstructured":"Jeganathan, N. & Sathananthan, M. Connective tissue disease-related interstitial lung disease: Prevalence, patterns, predictors, prognosis, and treatment. Lung. 198, 735\u2013759 (2020).","journal-title":"Lung"},{"key":"85338_CR9","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1177\/2397198320970394","volume":"6","author":"M Hughes","year":"2021","unstructured":"Hughes, M. et al. The role of ultrasound in systemic sclerosis: On the cutting edge to foster clinical and research advancement. J Scleroderma Relat Disord. 6, 123\u2013132 (2021).","journal-title":"J. Scleroderma Relat. Disord."},{"key":"85338_CR10","doi-asserted-by":"publisher","first-page":"1445923","DOI":"10.3389\/fphar.2024.1445923","volume":"15","author":"K B\u0105czek","year":"2024","unstructured":"B\u0105czek, K. & Piotrowski, W. J. Lung fibrosis in sarcoidosis. Is there a place for antifibrotics? Front Pharmacol. 15, 1445923 (2024).","journal-title":"Front. Pharmacol."},{"key":"85338_CR11","doi-asserted-by":"publisher","first-page":"00597","DOI":"10.1183\/23120541.00597-2021","volume":"8","author":"O Hilberg","year":"2022","unstructured":"Hilberg, O. et al. Epidemiology of interstitial lung diseases and their progressive-fibrosing behaviour in six European countries. ERJ Open Res. 8, 00597\u201302021 (2022).","journal-title":"ERJ Open Res."},{"key":"85338_CR12","doi-asserted-by":"crossref","unstructured":"Rossides, M., Darlington, P., Kullberg, S. & Arkema, E. V. Sarcoidosis: Epidemiology and clinical insights. J Intern Med. 293, (2023).","DOI":"10.1111\/joim.13629"},{"key":"85338_CR13","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1001\/jama.2022.1570","volume":"327","author":"JA Belperio","year":"2022","unstructured":"Belperio, J. A. et al. Diagnosis and treatment of pulmonary sarcoidosis: A review. JAMA. 327, 856\u2013867 (2022).","journal-title":"JAMA"},{"key":"85338_CR14","unstructured":"Raghu, G. et al. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: An official ATS\/ERS\/JRS\/ALAT clinical practice guideline. Am J Respir Crit Care Med. 205, (2022)."},{"key":"85338_CR15","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/S2213-2600(19)30172-9","volume":"7","author":"G Raghu","year":"2019","unstructured":"Raghu, G. et al. Long-term treatment with recombinant human pentraxin 2 protein in patients with idiopathic pulmonary fibrosis: An open-label extension study. Lancet Respir Med. 7, 657\u2013664 (2019).","journal-title":"Lancet Respir. Med."},{"key":"85338_CR16","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0206-2022","volume":"32","author":"M Kolb","year":"2023","unstructured":"Kolb, M., Crestani, B. & Maher, T. M. Phosphodiesterase 4B inhibition: A potential novel strategy for treating pulmonary fibrosis. Eur Respir Rev. 32, 220206 (2023).","journal-title":"Eur. Respir. Rev."},{"key":"85338_CR17","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1056\/NEJMoa2201737","volume":"386","author":"L Richeldi","year":"2022","unstructured":"Richeldi, L. et al. Trial of a preferential phosphodiesterase 4B inhibitor for idiopathic pulmonary fibrosis. N Engl J Med. 386, 2178\u20132187 (2022).","journal-title":"N. Engl. J. Med."},{"key":"85338_CR18","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/S2213-2600(18)30181-4","volume":"6","author":"TM Maher","year":"2018","unstructured":"Maher, T. M. et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): A phase 2a randomised placebo-controlled trial. Lancet Respir Med. 6, 627\u2013635 (2018).","journal-title":"Lancet Respir. Med."},{"key":"85338_CR19","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.chest.2018.08.1058","volume":"154","author":"SM Palmer","year":"2018","unstructured":"Palmer, S. M. et al. Randomized, double-blind, placebo-controlled, phase 2 trial of BMS-986020, a lysophosphatidic acid receptor antagonist for the treatment of idiopathic pulmonary fibrosis. Chest. 154, 1061\u20131069 (2018).","journal-title":"Chest"},{"key":"85338_CR20","doi-asserted-by":"crossref","unstructured":"Nelson, M. R. et al. The support of human genetic evidence for approved drug indications. Nat Genet. 47, (2015).","DOI":"10.1038\/ng.3314"},{"key":"85338_CR21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1008489","volume":"15","author":"EA King","year":"2019","unstructured":"King, E. A., Davis, J. W. & Degner, J. F. Are drug targets with genetic support twice as likely to be approved? Revised estimates of the impact of genetic support for drug mechanisms on the probability of drug approval. PLoS Genet. 15, e1008489 (2019).","journal-title":"PLoS Genet."},{"key":"85338_CR22","doi-asserted-by":"crossref","unstructured":"Ruscitti, P. et al. Tailoring the treatment of inflammatory rheumatic diseases by a better stratification and characterization of the clinical patient heterogeneity. Findings from a systematic literature review and experts\u2019 consensus. Autoimmun Rev. 23, (2024).","DOI":"10.1016\/j.autrev.2024.103581"},{"key":"85338_CR23","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/s41586-023-06592-6","volume":"622","author":"BB Sun","year":"2023","unstructured":"Sun, B. B. et al. Plasma proteomic associations with genetics and health in the UK Biobank. Nature. 622, 329\u2013338 (2023).","journal-title":"Nature"},{"key":"85338_CR24","doi-asserted-by":"crossref","unstructured":"Sollis, E. et al. The NHGRI-EBI GWAS Catalog: Knowledgebase and deposition resource. Nucleic Acids Res. 51, (2023).","DOI":"10.1093\/nar\/gkac1010"},{"key":"85338_CR25","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1038\/s41586-022-05473-8","volume":"613","author":"MI Kurki","year":"2023","unstructured":"Kurki, M. I. et al. FinnGen provides genetic insights from a well-phenotyped isolated population. Nature. 613, 508\u2013518 (2023).","journal-title":"Nature"},{"key":"85338_CR26","unstructured":"UK Biobank\u2014Neale lab. UK Biobank\u2014Neale lab. http:\/\/www.nealelab.is\/uk-biobank."},{"key":"85338_CR27","doi-asserted-by":"publisher","first-page":"1700991","DOI":"10.1183\/13993003.00991-2017","volume":"51","author":"JC Schupp","year":"2018","unstructured":"Schupp, J. C. et al. Phenotypes of organ involvement in sarcoidosis. Eur Respir J. 51, 1700991 (2018).","journal-title":"Eur. Respir. J."},{"key":"85338_CR28","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/s41588-022-01051-w","volume":"54","author":"J Zhang","year":"2022","unstructured":"Zhang, J. et al. Plasma proteome analyses in individuals of European and African ancestry identify cis-pQTLs and models for proteome-wide association studies. Nat Genet. 54, 593\u2013602 (2022).","journal-title":"Nat. Genet."},{"key":"85338_CR29","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41586-018-0175-2","volume":"558","author":"BB Sun","year":"2018","unstructured":"Sun, B. B. et al. Genomic atlas of the human plasma proteome. Nature. 558, 73\u201379 (2018).","journal-title":"Nature"},{"key":"85338_CR30","doi-asserted-by":"publisher","first-page":"3268","DOI":"10.1038\/s41467-018-05512-x","volume":"9","author":"C Yao","year":"2018","unstructured":"Yao, C. et al. Genome-wide mapping of plasma protein QTLs identifies putatively causal genes and pathways for cardiovascular disease. Nat Commun. 9, 3268 (2018).","journal-title":"Nat. Commun."},{"key":"85338_CR31","doi-asserted-by":"publisher","first-page":"eabj1541","DOI":"10.1126\/science.abj1541","volume":"374","author":"M Pietzner","year":"2021","unstructured":"Pietzner, M. et al. Mapping the proteo-genomic convergence of human diseases. Science. 374, eabj1541 (2021).","journal-title":"Science"},{"key":"85338_CR32","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1038\/s41588-021-00978-w","volume":"53","author":"E Ferkingstad","year":"2021","unstructured":"Ferkingstad, E. et al. Large-scale integration of the plasma proteome with genetics and disease. Nat Genet. 53, 1712\u20131721 (2021).","journal-title":"Nat. Genet."},{"key":"85338_CR33","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1001\/jama.2021.18236","volume":"326","author":"VW Skrivankova","year":"2021","unstructured":"Skrivankova, V. W. et al. Strengthening the reporting of observational studies in epidemiology using mendelian randomization: The STROBE-MR statement. JAMA. 326, 1614\u20131621 (2021).","journal-title":"JAMA"},{"key":"85338_CR34","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k601","volume":"362","author":"NM Davies","year":"2018","unstructured":"Davies, N. M., Holmes, M. V. & Davey Smith, G. Reading mendelian randomisation studies: A guide, glossary, and checklist for clinicians. BMJ. 362, k601 (2018).","journal-title":"BMJ"},{"key":"85338_CR35","doi-asserted-by":"publisher","first-page":"3443","DOI":"10.1158\/0008-5472.CAN-20-0985","volume":"80","author":"S Lin","year":"2020","unstructured":"Lin, S., Brown, D. W. & Machiela, M. J. LDtrait: An online tool for identifying published phenotype associations in linkage disequilibrium. Cancer Res. 80, 3443\u20133446 (2020).","journal-title":"Cancer Res."},{"key":"85338_CR36","doi-asserted-by":"publisher","first-page":"186","DOI":"10.12688\/wellcomeopenres.15555.1","volume":"4","author":"S Burgess","year":"2019","unstructured":"Burgess, S. et al. Guidelines for performing mendelian randomization investigations: Update for summer 2023. Wellcome Open Res. 4, 186 (2019).","journal-title":"Wellcome Open Res."},{"key":"85338_CR37","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.34408","volume":"7","author":"G Hemani","year":"2018","unstructured":"Hemani, G. et al. The MR-Base platform supports systematic causal inference across the human phenome. Elife. 7, e34408 (2018).","journal-title":"Elife"},{"key":"85338_CR38","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1002\/gepi.22077","volume":"41","author":"S Burgess","year":"2017","unstructured":"Burgess, S., Zuber, V., Valdes-Marquez, E., Sun, B. B. & Hopewell, J. C. Mendelian randomization with fine-mapped genetic data: Choosing from large numbers of correlated instrumental variables. Genet Epidemiol. 41, 714\u2013725 (2017).","journal-title":"Genet. Epidemiol."},{"key":"85338_CR39","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1038\/s41380-022-01507-9","volume":"27","author":"Y Deng","year":"2022","unstructured":"Deng, Y. et al. Identifying causal genes for depression via integration of the proteome and transcriptome from brain and blood. Mol Psychiatry. 27, 2849\u20132857 (2022).","journal-title":"Mol. Psychiatry"},{"key":"85338_CR40","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1038\/s41588-021-00931-x","volume":"53","author":"S Sakaue","year":"2021","unstructured":"Sakaue, S. et al. A cross-population atlas of genetic associations for 220 human phenotypes. Nat Genet. 53, 1415\u20131424 (2021).","journal-title":"Nat. Genet."},{"key":"85338_CR41","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/S2213-2600(20)30364-7","volume":"9","author":"A Duckworth","year":"2021","unstructured":"Duckworth, A. et al. Telomere length and risk of idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease: A mendelian randomisation study. Lancet Respir Med. 9, 285\u2013294 (2021).","journal-title":"Lancet Respir. Med."},{"key":"85338_CR42","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1038\/s41588-021-00954-4","volume":"53","author":"L Jiang","year":"2021","unstructured":"Jiang, L., Zheng, Z., Fang, H. & Yang, J. A generalized linear mixed model association tool for biobank-scale data. Nat Genet. 53, 1616\u20131621 (2021).","journal-title":"Nat. Genet."},{"key":"85338_CR43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1006706","volume":"13","author":"L Folkersen","year":"2017","unstructured":"Folkersen, L. et al. Mapping of 79 loci for 83 plasma protein biomarkers in cardiovascular disease. PLoS Genet. 13, e1006706 (2017).","journal-title":"PLoS Genet."},{"key":"85338_CR44","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1004383","volume":"10","author":"C Giambartolomei","year":"2014","unstructured":"Giambartolomei, C. et al. Bayesian test for colocalisation between pairs of genetic association studies using summary statistics. PLoS Genet. 10, e1004383 (2014).","journal-title":"PLoS Genet."},{"key":"85338_CR45","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1038\/s41588-019-0404-0","volume":"51","author":"B Liu","year":"2019","unstructured":"Liu, B., Gloudemans, M. J., Rao, A. S., Ingelsson, E. & Montgomery, S. B. Abundant associations with gene expression complicate GWAS follow-up. Nat Genet. 51, 768\u2013769 (2019).","journal-title":"Nat. Genet."},{"key":"85338_CR46","doi-asserted-by":"publisher","first-page":"2003979","DOI":"10.1183\/13993003.03979-2020","volume":"59","author":"T Nakanishi","year":"2022","unstructured":"Nakanishi, T. et al. Genetically increased circulating FUT3 level leads to reduced risk of idiopathic pulmonary fibrosis: A Mendelian randomisation study. Eur Respir J. 59, 2003979 (2022).","journal-title":"Eur. Respir. J."},{"key":"85338_CR47","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1080\/07853890.2022.2063375","volume":"54","author":"C Tana","year":"2022","unstructured":"Tana, C. et al. Comorbidities of sarcoidosis. Ann Med. 54, 1014\u20131035 (2022).","journal-title":"Ann. Med."},{"key":"85338_CR48","doi-asserted-by":"publisher","first-page":"1802153","DOI":"10.1183\/13993003.021532018","volume":"54","author":"Y Kaiser","year":"2019","unstructured":"Kaiser, Y., Eklund, A. & Grunewald, J. Moving target: Shifting the focus to pulmonary sarcoidosis as an autoimmune spectrum disorder. Eur Respir J. 54, 1802153 (2019).","journal-title":"Eur. Respir. J."},{"key":"85338_CR49","doi-asserted-by":"crossref","unstructured":"Antonelli, A., Fazzi, P., Fallahi, P., Ferrari, S. M. & Ferrannini, E. Prevalence of hypothyroidism and Graves disease in sarcoidosis. Chest. 130, (2006).","DOI":"10.1378\/chest.130.2.526"},{"key":"85338_CR50","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1378\/chest.95.3.604","volume":"95","author":"RF Kucera","year":"1989","unstructured":"Kucera, R. F. et al. A possible association of rheumatoid arthritis and sarcoidosis. Chest. 95, 604\u2013606 (1989).","journal-title":"Chest"},{"key":"85338_CR51","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0123057","volume":"10","author":"OA Andreassen","year":"2015","unstructured":"Andreassen, O. A. et al. Abundant genetic overlap between blood lipids and immune-mediated diseases indicates shared molecular genetic mechanisms. PLoS One 10, e0123057 (2015).","journal-title":"PLoS One"},{"key":"85338_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110183","volume":"127","author":"H Li","year":"2020","unstructured":"Li, H. et al. Src family kinases and pulmonary fibrosis: A review. Biomed Pharmacother. 127, 110183 (2020).","journal-title":"Biomed. Pharmacother."},{"key":"85338_CR53","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1093\/toxsci\/kfab133","volume":"185","author":"J Ning","year":"2022","unstructured":"Ning, J. et al. N6-methyladenosine modification of CDH1 mRNA promotes PM2.5-induced pulmonary fibrosis via mediating epithelial mesenchymal transition. Toxicol Sci. 185, 143\u2013157 (2022).","journal-title":"Toxicol. Sci."},{"key":"85338_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2020.101766","volume":"38","author":"P Liu","year":"2021","unstructured":"Liu, P. et al. The NRF2-LOC344887 signaling axis suppresses pulmonary fibrosis. Redox Biol. 38, 101766 (2021).","journal-title":"Redox Biol."},{"key":"85338_CR55","doi-asserted-by":"publisher","first-page":"eabm5164","DOI":"10.1126\/sciadv.abm5164","volume":"8","author":"DH Katz","year":"2022","unstructured":"Katz, D. H. et al. Proteomic profiling platforms head to head: Leveraging genetics and clinical traits to compare aptamer- and antibody-based methods. Sci Adv. 8, eabm5164 (2022).","journal-title":"Sci. Adv."},{"key":"85338_CR56","doi-asserted-by":"publisher","first-page":"6822","DOI":"10.1038\/s41467-021-27164-0","volume":"12","author":"M Pietzner","year":"2021","unstructured":"Pietzner, M. et al. Synergistic insights into human health from aptamer- and antibody-based proteomic profiling. Nat Commun. 12, 6822 (2021).","journal-title":"Nat. Commun."},{"key":"85338_CR57","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.3390\/cells11091557","volume":"11","author":"B Karakaya","year":"2022","unstructured":"Karakaya, B. et al. ANXA11 rs1049550 associates with L\u00f6fgren\u2019s syndrome and chronic sarcoidosis patients. Cells. 11, 1557 (2022).","journal-title":"Cells"},{"key":"85338_CR58","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.mam.2008.08.001","volume":"29","author":"DR Edwards","year":"2008","unstructured":"Edwards, D. R., Handsley, M. M. & Pennington, C. J. The ADAM metalloproteinases. Mol Asp Med. 29, 258\u2013289 (2008).","journal-title":"Mol. Asp. Med."},{"key":"85338_CR59","doi-asserted-by":"publisher","first-page":"L129","DOI":"10.1152\/ajplung.00261.2005","volume":"291","author":"D Okutani","year":"2006","unstructured":"Okutani, D., Lodyga, M., Han, B. & Liu, M. Src protein tyrosine kinase family and acute inflammatory responses. Am J Physiol Lung Cell Mol Physiol. 291, L129-141 (2006).","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"85338_CR60","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1007\/s00134-012-2498-z","volume":"38","author":"T Oyaizu","year":"2012","unstructured":"Oyaizu, T. et al. Src tyrosine kinase inhibition prevents pulmonary ischemia-reperfusion-induced acute lung injury. Intensiv Care Med. 38, 894\u2013905 (2012).","journal-title":"Intensiv. Care Med."},{"key":"85338_CR61","doi-asserted-by":"publisher","first-page":"5637","DOI":"10.1038\/s41467-022-33193-0","volume":"13","author":"B Jaeger","year":"2022","unstructured":"Jaeger, B. et al. Airway basal cells show a dedifferentiated KRT17highPhenotype and promote fibrosis in idiopathic pulmonary fibrosis. Nat Commun. 13, 5637 (2022).","journal-title":"Nat. Commun."},{"key":"85338_CR62","doi-asserted-by":"publisher","first-page":"5882","DOI":"10.1038\/s41467-023-41614-x","volume":"14","author":"I Barbayianni","year":"2023","unstructured":"Barbayianni, I. et al. SRC and TKS5 mediated podosome formation in fibroblasts promotes extracellular matrix invasion and pulmonary fibrosis. Nat Commun. 14, 5882 (2023).","journal-title":"Nat. Commun."},{"key":"85338_CR63","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/j.bbadis.2012.06.008","volume":"1832","author":"C Beyer","year":"2013","unstructured":"Beyer, C. & Distler, J. H. W. Tyrosine kinase signaling in fibrotic disorders: Translation of basic research to human disease. Biochim Biophys Acta. 1832, 897\u2013904 (2013).","journal-title":"Biochim. Biophys. Acta"},{"key":"85338_CR64","doi-asserted-by":"publisher","first-page":"F721","DOI":"10.1152\/ajprenal.00141.2017","volume":"313","author":"J Wang","year":"2017","unstructured":"Wang, J. & Zhuang, S. Src family kinases in chronic kidney disease. Am J Physiol Renal Physiol. 313, F721\u2013F728 (2017).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"85338_CR65","doi-asserted-by":"publisher","first-page":"2826","DOI":"10.1002\/art.38109","volume":"65","author":"BB B\u00f6hm","year":"2013","unstructured":"B\u00f6hm, B. B., Freund, I., Krause, K., Kinne, R. W. & Burkhardt, H. ADAM15 adds to apoptosis resistance of synovial fibroblasts by modulating focal adhesion kinase signaling. Arthritis Rheum. 65, 2826\u20132834 (2013).","journal-title":"Arthritis Rheum."},{"key":"85338_CR66","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1002\/art.40667","volume":"71","author":"T Janczi","year":"2019","unstructured":"Janczi, T. et al. ADAM15 in apoptosis resistance of synovial fibroblasts: Converting Fas\/CD95 death signals into the activation of prosurvival pathways by calmodulin recruitment. Arthritis Rheumatol. 71, 63\u201372 (2019).","journal-title":"Arthritis Rheumatol."},{"key":"85338_CR67","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.celrep.2018.03.067","volume":"23","author":"M Black","year":"2018","unstructured":"Black, M. et al. FOXF1 Inhibits pulmonary fibrosis by preventing CDH2-CDH11 cadherin switch in myofibroblasts. Cell Rep. 23, 442\u2013458 (2018).","journal-title":"Cell Rep."},{"key":"85338_CR68","doi-asserted-by":"publisher","first-page":"L71","DOI":"10.1152\/ajplung.00212.2010","volume":"301","author":"C Marmai","year":"2011","unstructured":"Marmai, C. et al. Alveolar epithelial cells express mesenchymal proteins in patients with idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 301, L71\u201378 (2011).","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"85338_CR69","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/j.jhep.2016.05.007","volume":"65","author":"G Giannelli","year":"2016","unstructured":"Giannelli, G., Koudelkova, P., Dituri, F. & Mikulits, W. Role of epithelial to mesenchymal transition in hepatocellular carcinoma. J Hepatol. 65, 798\u2013808 (2016).","journal-title":"J. Hepatol."},{"key":"85338_CR70","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1172\/JCI200320530","volume":"112","author":"R Kalluri","year":"2003","unstructured":"Kalluri, R. & Neilson, E. G. Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest. 112, 1776\u20131784 (2003).","journal-title":"J. Clin. Invest."},{"key":"85338_CR71","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.toxlet.2016.12.016","volume":"267","author":"W Tang","year":"2017","unstructured":"Tang, W. et al. Maternal exposure to fine particulate air pollution induces epithelial-to-mesenchymal transition resulting in postnatal pulmonary dysfunction mediated by transforming growth factor-\u03b2\/Smad3 signaling. Toxicol Lett. 267, 11\u201320 (2017).","journal-title":"Toxicol. Lett."},{"key":"85338_CR72","doi-asserted-by":"crossref","unstructured":"Yan, L. et al. Epithelium-derived exosomes promote silica nanoparticles-induced pulmonary fibroblast activation and collagen deposition via modulating fibrotic signaling pathways and their epigenetic regulations. J Nanobiotechnol. 22, (2024).","DOI":"10.1186\/s12951-024-02609-y"},{"key":"85338_CR73","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1002\/path.1249","volume":"199","author":"S Agyekum","year":"2003","unstructured":"Agyekum, S. et al. Expression of lymphotoxin-beta (LT-beta) in chronic inflammatory conditions. J Pathol. 199, 115\u2013121 (2003).","journal-title":"J. Pathol."},{"key":"85338_CR74","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1183\/09031936.98.12040926","volume":"12","author":"V Boussaud","year":"1998","unstructured":"Boussaud, V., Soler, P., Moreau, J., Goodwin, R. G. & Hance, A. J. Expression of three members of the TNF-R family of receptors (4\u20131BB, lymphotoxin-beta receptor, and Fas) in human lung. Eur Respir J. 12, 926\u2013931 (1998).","journal-title":"Eur. Respir. J."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-85338-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-85338-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-85338-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T01:04:38Z","timestamp":1737162278000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-85338-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,17]]},"references-count":74,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["85338"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-85338-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,17]]},"assertion":[{"value":"9 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2293"}}